| Filed On | Filing |
|---|---|
| 16 Nov 2026 |
8-K: Results of Operations and Financial Condition
Date of Report (Date of earliest event reported): November 16, 2026 |
| 16 Nov 2026 | SCHEDULE 13G/A |
| 16 Nov 2026 | 10-Q |
| 29 Oct 2026 |
Form 4: Manning Meredith, Director
Granted 3,350 Restricted Stock Units · Granted 27,000 Stock Options |
| 01 Oct 2026 |
Form 3: Manning Meredith, Director
No securities owned |
| 29 Sep 2026 |
8-K: Departure/Election of Directors or Officers; Compensation; Other Events
Resubmission of NDA includes Chemistry, Manufacturing, and Controls (CMC) data from a new drug product manufacturing vendor |
| 28 Sep 2026 |
8-K: Other Events
On September 3, 2026, a securities class action lawsuit was filed in United States District Court for the Northern District of California against Unicycive Therapeutics, Inc. (the “Company”) and certain of its officers. This action alleg... |
| 14 Aug 2026 | SCHEDULE 13G/A |
| 14 Aug 2026 | SCHEDULE 13G/A |
| 12 Aug 2026 |
8-K: Results of Operations and Financial Condition
- Company expects to resubmit New Drug Application (NDA) for oxylanthanum carbonate (OLC) assuming completion of successful inspection of third-party manufacturing vendor |
| 12 Aug 2026 | QUARTERLY REPORT |
| 30 Jul 2026 | SCHEDULE 13G |
| 28 Jul 2026 |
Form 4/A: Kenkare-Mitra Sara, Director
Granted 47,941 Restricted Stock Units |
| 28 Jul 2026 |
Form 4/A: Laumas Sandeep, Director
Granted 47,941 Restricted Stock Units |
| 08 Jul 2026 | SCHEDULE 13G/A |
| 02 Jul 2026 |
8-K: Other Events
The Company had an ending cash balance of approximately $61.4 million as of June 30, 2026. |
| 01 Jul 2026 | 144 |
| 22 Jun 2026 | CURRENT REPORT |
| 22 Jun 2026 |
8-K: Submission of Matters to a Vote of Security Holders
On June 19, 2025, Unicycive Therapeutics, Inc. (the “Company”) held its Annual Meeting of Stockholders (the “Annual Meeting”). A total of 14,964,159 shares of common stock, constituting a quorum, were represented in person or by valid pr... |
| 15 Jun 2026 | EFFECT |
Loading...